Multi-omics Market - By Products & Services (Products {Instruments, Consumables}, Services), Type (Single-cell, Bulk), Platform (Genomics), Application (Cell Biology), End-use (Academic & Research Organizations), Global Forecast, 2023-2032

Multi-omics Market - By Products & Services (Products {Instruments, Consumables}, Services), Type (Single-cell, Bulk), Platform (Genomics), Application (Cell Biology), End-use (Academic & Research Organizations), Global Forecast, 2023-2032

Multi-omics Market Size

Multi-omics Market size was valued at USD 2.9 billion in 2022 and is estimated to grow at a CAGR of 15.2% between 2023 and 2032. One of the primary drivers is the continuous evolution and refinement of omics technologies. Advances in spatial genomics, transcriptomics, proteomics, metabolomics, and other omics disciplines contribute to the generation of vast and intricate datasets, providing researchers with a more comprehensive understanding of biological systems.

Additionally, the increasing adoption of multi-omics approaches in various research domains, from basic biological studies to clinical applications, is fuelling market growth. Furthermore, the rising demand for personalized medicine and targeted therapies amplifies the market's expansion. All these aforementioned factors collectively contribute to the advancement of the market.
 

Multi-omics refers to an approach in biological research that involves the integration of data from multiple omics disciplines. Omics disciplines include genomics, transcriptomics, proteomics, metabolomics, and other omics fields that aim to characterize and quantify the components of biological systems.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the multi-omics market. Multi-omics analysis platforms played a crucial role in the diagnosis and classification of COVID-19. The urgency to understand the virus and its effects on human biology has accelerated research in these areas, fostered the demand for multi-omics technologies. Also, the pandemic highlighted the importance of comprehensive data integration and analysis to unravel the complexities of disease pathways and host responses. The long-term impact of COVID-19 on the market is likely to include sustained growth as researchers continue to leverage these technologies for a deeper understanding of complex biological systems.

Multi-omics Market Trends

• Rising government initiatives and increased funding have emerged as pivotal drivers propelling the growth of the market. Governments worldwide are recognizing the transformative potential of multi-omics technologies in revolutionizing healthcare studies. For instance, in November 2022, the Texas A&M University System has received a USD 1.19 million grant from the National Institutes of Health (NIH) for a multidisciplinary collaboration to study the intricate connections between genomics, nutrition and health.
   
• Moreover, advancements in omics technologies have further propelled the growth of the market. These advancements have led to unprecedented insights into the intricacies of cellular processes, disease mechanisms, and personalized medicine.
   

As these technologies become more sophisticated and accessible, their application in research, diagnostics, and therapeutic development has expanded, thereby driving the demand for multi-omics solutions.
 

Multi-omics Market Analysis

Based on products & services, the market is segmented into products & services. The products segment is further segmented into instruments, consumables, and software. The products segment dominated the market in 2022 with a revenue of USD 1.7 billion.
 

• The high demand for multi-omics products is fueled by the growing recognition of their potential to unravel the complexities of diseases, facilitate biomarker discovery, and pave the way for more targeted and effective therapeutic interventions.
   
• Further, rising awareness and heightened interest in omics technologies is propelling innovations in the development of cutting-edge products, such as integrated omics platforms, high-throughput instruments, and sophisticated data analysis tools.
   
• As advancements in multi-omics technologies continues to accelerate, the demand for innovative and integrated products is anticipated to rise, thus propelling the segment expansion.
   

Based on the type, the multi-omics market is bifurcated into single cell multi-omics and bulk omics. The single cell omics segment dominated the market in 2022 with a market share of 72.6%.
 

• The increasing adoption of single-cell omics tools is driven by their ability to capture intricate molecular signatures at a single-cell level, providing a more comprehensive and accurate depiction of biological processes.
   
• Researchers and clinicians are leveraging these advancements to unravel the complexities of diseases, identify rare cell populations, and tailor personalized therapeutic strategies.
   
• Thus, as the demand for precise and tailored healthcare solutions continues to rise, the high growth of the single-cell omics segment is expected to continue over the analysis period.
   

Based on the platform, the multi-omics market is categorized into genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms. The genomics segment is anticipated to grow at a CAGR of 15% between 2023 - 2032.
 

• The genomics segment has experienced remarkable and sustained growth in recent years. The rapid evolution of high-throughput sequencing technologies, coupled with decreasing costs and enhanced computational capabilities, has fueled expansion in genomics research.
   
• Furthermore, as researchers and organizations strive to unlock the vast potential of genomics data and its growing utilization in personalized medicine, the market is poised for high progress.
   

By application, the multi-omics market is categorized into cell biology, oncology, neurology, immunology, and other applications. The oncology segment is poised for high growth and is anticipated to reach USD 3.3 billion by 2032.
 

• The integration of genomics, transcriptomics, proteomics, and metabolomics has allowed researchers and clinicians to unravel the complex landscape of cancer at a molecular level, paving the way for more targeted therapies.
   
• Also, advancements in technology and data analysis tools have streamlined the process of generating and interpreting multi-omics data, making it more accessible and applicable in clinical settings.
   

By end-use, the multi-omics market is segmented into academic & research organizations, pharmaceutical & biotechnology companies, hospital and diagnostic laboratories, and other end-users. Wide application of multi-omics data in research, is anticipated to propel the growth of academic and research organizations.
 

• Academic & research organizations have embraced multi-omics as a powerful tool to unravel the complexities of diseases, identify biomarkers, and personalize therapeutic strategies.
   
• With their substantial budgets and focus on interdisciplinary research, academic institutes and research centers continue to be key drivers of innovation in the multi-omics industry, thereby aiding in high segment development.
   

North America accounted for the largest market share of 46.8% of the global multi-omics market in 2022.
 

• The region's high growth can be attributed to a confluence of factors, including substantial investments in research and development, a robust infrastructure for healthcare innovation, and a proactive regulatory environment fostering the adoption of multi-omics approaches.
   
• Also, collaborations between academic institutions, biotechnology companies, and pharmaceutical enterprises have further accelerated the development and commercialization of cutting-edge multi-omics solutions.
   

Multi-omics Market Share

The market is characterized by diverse players competing in the industry. Becton, Dickinson and Company, Thermo Fisher Scientific Inc., and Illumina, Inc. account for significant market share. These prominent players thrive through a combination of strategic initiatives, investing in research and development, geographical expansion, strategic approaches, product diversification, and regulatory compliance. The foremost market players operating in the multi-omics industry is as mentioned below

• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• Illumina, Inc
• Danaher
• PerkinElmer Inc.
• Shimadzu Corporation
• Bruker
• QIAGEN
• Agilent Technologies, Inc.
• BGI
• 10x Genomics
• CYTENA GmbH
   

Multi-omics Industry News

• In September 2023, 10x Genomics, Inc. announced the commercial availability of a new kit to expand the capabilities of its chromium single cell gene expression flex assay to include high throughput multi-omic cellular profiling. The new kit enables streamlined, multi-omic characterization of cell populations so that researchers can expand their options at a larger scale and detect simultaneous gene and protein expression. This strategy helped the company to expand its product offerings.
   
• In February 2023, Becton, Dickinson and Company launched a high-throughput single-cell multiomics platform, Rhapsody HT Xpress System to expand scope of scientific discovery. This new system enables scientists to isolate, barcode and analyse single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analysers. This strategy is anticipated to help the company to widen the applications of its product and cater to a larger customer base.
   

The multi-omics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product & Services, 2018 – 2032 (USD Million)

• Products
• Instruments
• Consumables
• Software

• Services

By Type, 2018 – 2032 (USD Million)

• Single-cell multi-omics
• Bulk multi-omics

By Platform, 2018 – 2032 (USD Million)

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Integrated omics platforms

By Application, 2018 – 2032 (USD Million)

• Oncology
• Cell biology
• Neurology
• Immunology
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Academic and research organizations
• Pharmaceutical & biotechnology companies
• Hospital and diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa